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Dear Editor,
The myelodysplastic syndromes (MDS) are a group of clonal 
disorders of the hematopoietic stem cell, characterized by 
cytopenia(s), dysplasia of one or more of the myeloid lineages, 
ineffective hematopoiesis, and an increased risk of developing 
acute myeloid leukemia (AML).1 Refractory anemia with ringed 
sideroblasts and thrombocytosis (RARS-T), is a provisional entity 
that, according to the World Health Organization (WHO), joined 
the group of myelodysplastic/myeloproliferative neoplasms 
(MDS/MPN).2 The diagnostic criteria for RARS-T are the presence 
of persistent thrombocytosis (above 600 × 109/L), ≥ 15% ringed 
sideroblasts, and < 5% blasts in the bone marrow.3,4 An acquired 
JAK2-V617F mutation, resulting in a substitution of valine for 
phenylalanine at codon 617 of the JAK2 gene, is reported in 
90% of cases of Polycythemia vera (PV), and in about 50% of 
cases of myelofibrosis (MF), and essential thrombocythemia 
(ET).4 The JAK2-V617F mutation is positive in about 60% of 
cases of RARS-T, and in a minority of cases in other subtypes 
of MDS/MPN.5 Studies have evaluated the relationship between 
the state of the JAK2-V617F to morphological, clinical, and 
laboratory parameters, and survival in RARS-T,6 suggesting that 
the mutation confers a favorable prognosis, and is associated 
with an increase in hemoglobin, decrease in mean corpuscular 
volume (MCV), and increases in leukocyte and platelet counts. 
The figures below show the case of an 80-year-old JAK2-
V617F-positive male patient with RARS-T and systemic 
hypertension, who was submitted to radiotherapy in 2007 for 
a prostate adenocarcinoma: 
Myelogram: Dyserythropoiesis and dysmegakaryopoiesis 
above 10%; asynchrony of maturation and binucleation; presence 
of micromegakaryocytes and hypolobulated megakaryocytes; 
1% of plasmocyte, and 81% ringed sideroblasts. 
Bone marrow biopsy: hypercellular marrow disorder 
architecture, characterized by megaloblastoid erythroblasts, 
peripheral megakaryocytes, and a slight increase in the 
network of reticulin myelofibrosis (grade I). Cytogenetics 
revealed 46, XY karyotype. Immunohistochemical expression 
was p53 negative. Hematological parameters: hemoglobin: 7.8 
g/dL; leukocyte count: 7.740 × 103/μL and platelet count: 949 
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Figure 1 – Bone marrow with dysmegakaryopoiesis and 
dyserythropoiesis. Hematoxylin and eosin stain, original 
magnification 400×.
Figure 2 – Bone marrow biopsy with reticulin and interstitial 
condensation (grade I) Hematoxylin and eosin stain, original 
magnification 400×.
× 103/μL. Figure 1 illustrates the presence of megakaryocytes 
with separate cores, along with a nuclear hyperchromasia 
and cane aspect in band, observed megaloblastoid 
erythroblasts distributed in a dispersed interstitial manner 
with hematopoietic marrow dysmegakaryopoiesis and 
dyserythropoiesis. Figure 2 illustrates a bone marrow biopsy 
with reticulin and interstitial condensation (grade I). The 
images show the relevance of the histopathological findings of 
the bone marrow biopsy in diagnosing this rare subtype of MDS.
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